MitrendS in a nutshell
Smartphone- and tablet-based applications represent promising tools to evaluate the burden of disease and to monitor disability progression and treatment responses in patients with multiple sclerosis (pwMS).
In a collaborative research project, the MitrendS application for tablets is currently under development aiming to be a comprehensive tool to follow symptoms and neurologic impairment, including the motor function of the hand and arm, cognition, fatigue, mood, quality of life and gait. MitrendS offers regular self-monitoring for patients at home and aims at patient empowerment by actively participating in disease management. Regular remote monitoring provides the opportunity to capture fluctuations of symptoms or disease progression and evaluate treatment responses based on personalized outcome measures.
Currently, three tests are implemented in MitrendS: The Line-Test, the Move-Dots-Test and a digital version of the Symbol-Digit-Modalities-Test (SDMT). In the Line-Test the subjects follow multiple curved lines in succession. Together with the Move-Dots-Test, where one uses thumb, index- and middle finger to rotate and move dots to a specific spot on the screen, the motor function of hand and arm are assessed. The digitalized SDMT can be performed by patients remotely. Several validated questionnaires, including the Fatigue Severity Scale and the Multiple Sclerosis Impact Scale, can be used to report patientbased outcomes on a regular basis directly from the app. Further tests are currently being developed to extend neurological assessments with the aim to offer a comprehensive test suite for pwMS.
MitrendS will be used in a prospective cohort study at the Department of Neuroimmunology and Multiple Sclerosis Research of the University Hospital Zurich. The app’s validity and psychometric properties will be investigated in pwMS and healthy volunteers (Citizen Science). The Citizen Science cohort will actively contribute to the collection of normative data.
Each participant is free to continue using the app after the trial period. In this way, longterm data can be collected, and the course of the disease monitored.
Data is stored in the patient´s account on the MIDATA platform and thus remains entirely owned and controlled by the patient. The MIDATA cooperative is a completely independent platform and supports datadriven research through patient empowerment and citizen science approaches. The MIDATA platform provides a personal and secure environment to merge data collected by MitrendS with health-related data from hospitals and physicians to be used for outcome assessment and research. Patients decide to whom they allow access to their data. They can share their data pseudonymized to participate in appropriate studies or provide it to their treating physicians. In the case of MitrendS, participants receive evaluations of test performance directly via the MIDATA platform.
For further information about MIDATA and its structure visit www.midata.coop